Tilray Exports Medical Cannabis Extracts to the European Union
Tilray is supplying pharmacies around Croatia with orally administered medical cannabis products through a partnership with the Croatian Institute of Immunology, which will oversee distribution of Tilray products cultivated and processed at our facility in Nanaimo. After receipt of all necessary approvals and permits from the Croatian and Canadian regulatory authorities, Tilray announced the partnership at Croatias annual Media and Health Symposium in Gronjan this morning. Initially, two varieties of Tilray Liquid Capsules will be available in Croatia. One formulation contains 5.0 mg of THC and 5.0 mg of CBD per capsule. The other formulation contains 2.5 mg of THC and 2.0 mg of CBD per capsule.
Professor Ognjen Brborovi? PhD MD, Chairman of Croatias Committee for Medical Cannabis, welcomed the arrival of Tilray Liquid Capsules in Croatia. "It took eight months for the Committee for Medical Cannabis to deliver necessary documents needed to change Croatian legislation to get cannabis to Croatian patients. It took another eight months of diligent work with Tilray to secure all certificates and licenses needed to import and distribute cannabinoid preparations into the European Union from Canada and for actual production of the first batch of cannabis extract oil. I am glad that Croatia is the first EU country that will be able to assure patients first-class cannabis extract oil is available in pharmacies. I hope that patients in other EU countries will soon have the same opportunity," Dr. Brborovi? said.
This effort to facilitate legitimate medical access, further establishes Canada as a leading source of cannabis for medical and scientific applications globally. In May, Tilray received approval from Australias Therapeutic Goods Administration and the Queensland Department of Health to begin supplying a patient in Australia with medical cannabis via a federally administered Special Access Scheme. Earlier in the year, Tilray announced a clinical research trial in Australia in partnership with the Government of New South Wales, Chris OBrien Lifehouse and the University of Sydney to study the safety and efficacy of medicinal cannabis for patients suffering from chemotherapy-induced nausea and vomiting.
In the coming months, Tilray will announce several additional clinical research partnerships in Australia, Canada and Europe as well as further medical market partnerships in Europe. With todays announcement, Tilray becomes the first Canadian company to export medical cannabis products from the countrys federally regulated medical cannabis program.